Gholizadeh Siahmazgi Z, Irani S, Ghiaseddin A, Soutodeh F, Gohari Z, Afifeh J
    
    
    Res Pharm Sci. 2025; 19(6):669-682.
  
  
    PMID: 39911899
    
          PMC: 11792713.
    
          DOI: 10.4103/RPS.RPS_38_24.
      
 
                                  
  
    Leguay K, Kent O
    
    
    Onco Targets Ther. 2025; 18:147-159.
  
  
    PMID: 39882405
    
          PMC: 11776410.
    
          DOI: 10.2147/OTT.S496228.
      
 
                                  
  
    Qian J, Duan J, Cao D
    
    
    Turk J Gastroenterol. 2024; 35(11):849-858.
  
  
    PMID: 39549020
    
          PMC: 11562497.
    
          DOI: 10.5152/tjg.2024.24131.
      
 
                                  
  
    du Plessis J, Deroubaix A, Omar A, Penny C
    
    
    Curr Issues Mol Biol. 2024; 46(8):8600-8610.
  
  
    PMID: 39194723
    
          PMC: 11352951.
    
          DOI: 10.3390/cimb46080506.
      
 
                                  
  
    Chaudhary H, Cannon T, Winer A
    
    
    Drugs R D. 2024; 24(3):395-403.
  
  
    PMID: 39177935
    
          PMC: 11455815.
    
          DOI: 10.1007/s40268-024-00475-5.
      
 
                              
              
                              
                                      
  Effector Binding Sequentially Alters KRAS Dimerization on the Membrane: New Insights Into RAS-Mediated RAF Activation.
  
    Lee S, Eun H, Lee K
    
    
    Adv Sci (Weinh). 2024; 11(38):e2401530.
  
  
    PMID: 39138901
    
          PMC: 11481233.
    
          DOI: 10.1002/advs.202401530.
      
 
                                          
                                                          
  Molecular Dynamics Simulation on the Suppression Mechanism of Phosphorylation to Ser222 by Allosteric Inhibitors Targeting MEK1/2 Kinase.
  
    Mudedla S, Lee H, Kim J, Jang S, Doddareddy M, Sanam S
    
    
    ACS Omega. 2024; 9(29):31946-31956.
  
  
    PMID: 39072081
    
          PMC: 11270731.
    
          DOI: 10.1021/acsomega.4c03615.
      
 
                                          
                                                          
  MEK inhibitors: a promising targeted therapy for cardiovascular disease.
  
    Mohammed K, Madeddu P, Avolio E
    
    
    Front Cardiovasc Med. 2024; 11:1404253.
  
  
    PMID: 39011492
    
          PMC: 11247000.
    
          DOI: 10.3389/fcvm.2024.1404253.
      
 
                                          
                                                          
  Mechanism of Abnormal Activation of MEK1 Induced by Dehydroalanine Modification.
  
    Zhao Y, Du S, Zhao C, Li T, Tong S, Zhao L
    
    
    Int J Mol Sci. 2024; 25(13).
  
  
    PMID: 39000589
    
          PMC: 11242638.
    
          DOI: 10.3390/ijms25137482.
      
 
                                          
                                                          
  Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib.
  
    Gazzin A, Fornari F, Cardaropoli S, Carli D, Tartaglia M, Ferrero G
    
    
    Life (Basel). 2024; 14(6).
  
  
    PMID: 38929714
    
          PMC: 11204468.
    
          DOI: 10.3390/life14060731.
      
 
                                          
                                                          
  Lung Fibroblasts Take up Breast Cancer Cell-derived Extracellular Vesicles Partially Through MEK2-dependent Macropinocytosis.
  
    Wan Y, Zhao Y, Cao M, Wang J, Tran S, Song Z
    
    
    Cancer Res Commun. 2024; 4(1):170-181.
  
  
    PMID: 38259097
    
          PMC: 10802141.
    
          DOI: 10.1158/2767-9764.CRC-23-0316.
      
 
                                          
                                                          
  Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation.
  
    Godfrey L, Forster J, Liffers S, Schroder C, Koster J, Henschel L
    
    
    Clin Epigenetics. 2024; 16(1):13.
  
  
    PMID: 38229153
    
          PMC: 10792938.
    
          DOI: 10.1186/s13148-024-01623-z.
      
 
                                          
                                                          
  Architecture of the MKK6-p38α complex defines the basis of MAPK specificity and activation.
  
    Juyoux P, Galdadas I, Gobbo D, von Velsen J, Pelosse M, Tully M
    
    
    Science. 2023; 381(6663):1217-1225.
  
  
    PMID: 37708276
    
          PMC: 7615176.
    
          DOI: 10.1126/science.add7859.
      
 
                                          
                                                          
  How many kinases are druggable? A review of our current understanding.
  
    Anderson B, Rosston P, Ong H, Hossain M, Davis-Gilbert Z, Drewry D
    
    
    Biochem J. 2023; 480(16):1331-1363.
  
  
    PMID: 37642371
    
          PMC: 10586788.
    
          DOI: 10.1042/BCJ20220217.
      
 
                                          
                                                          
  The cardiac glycoside ZINC253504760 induces parthanatos-type cell death and G2/M arrest via downregulation of MEK1/2 phosphorylation in leukemia cells.
  
    Zhou M, Boulos J, Klauck S, Efferth T
    
    
    Cell Biol Toxicol. 2023; 39(6):2971-2997.
  
  
    PMID: 37322258
    
          PMC: 10693532.
    
          DOI: 10.1007/s10565-023-09813-w.
      
 
                                          
                                                          
  MKK4 Inhibitors-Recent Development Status and Therapeutic Potential.
  
    Katzengruber L, Sander P, Laufer S
    
    
    Int J Mol Sci. 2023; 24(8).
  
  
    PMID: 37108658
    
          PMC: 10144091.
    
          DOI: 10.3390/ijms24087495.
      
 
                                          
                                                          
  Experimental strategies to improve drug-target identification in mass spectrometry-based thermal stability assays.
  
    Phaneuf C, Aizikov K, Grinfeld D, Kreutzmann A, Mourad D, Lange O
    
    
    Commun Chem. 2023; 6(1):64.
  
  
    PMID: 37024568
    
          PMC: 10079678.
    
          DOI: 10.1038/s42004-023-00861-1.
      
 
                                          
                                                          
  Analysis of the ERK Pathway Cysteinome for Targeted Covalent Inhibition of RAF and MEK Kinases.
  
    Romany A, Liu R, Zhan S, Clayton J, Shen J
    
    
    J Chem Inf Model. 2023; 63(8):2483-2494.
  
  
    PMID: 37022803
    
          PMC: 10214248.
    
          DOI: 10.1021/acs.jcim.3c00014.
      
 
                                          
                                                          
  Investigating a Library of Flavonoids as Potential Inhibitors of a Cancer Therapeutic Target MEK2 Using in Silico Methods.
  
    AlZahrani W, Alghamdi S, Sohrab S, Rehan M
    
    
    Int J Mol Sci. 2023; 24(5).
  
  
    PMID: 36901876
    
          PMC: 10002492.
    
          DOI: 10.3390/ijms24054446.
      
 
                                          
                                                          
  Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2.
  
    Wang P, Jia X, Lu B, Huang H, Liu J, Liu X
    
    
    Signal Transduct Target Ther. 2023; 8(1):96.
  
  
    PMID: 36872366
    
          PMC: 9986241.
    
          DOI: 10.1038/s41392-023-01329-3.